Novel agents in the future: Therapy beyond anti‐TNF agents in inflammatory bowel disease | Zendy

Peng Jiang Chen | Zendy; Shen Jun | Zendy; Ran Zhi Hua | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Novel agents in the future: Therapy beyond anti‐TNF agents in inflammatory bowel disease

Author(s) -

Peng Jiang Chen,

Shen Jun,

Ran Zhi Hua

Publication year - 2014

Publication title -

journal of digestive diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.684

H-Index - 51

eISSN - 1751-2980

pISSN - 1751-2972

DOI - 10.1111/1751-2980.12193

Subject(s) - medicine , inflammatory bowel disease , tumor necrosis factor alpha , disease , crohn's disease , clinical trial , inflammatory bowel diseases , biologic agents , intensive care medicine , tumor necrosis factor α , infliximab , immunology

Anti‐tumor necrosis factor (TNF)‐α agents emerge as the hot spot in the last decade for treating patients with inflammatory bowel disease ( IBD ). The effect of anti‐ TNF ‐α agents is satisfactory; however, some patients fail to achieve clinical response. Fortunately, in recent years, great efforts have been made and multiple novel therapies have been developed in the treatment for IBD . In this article, we aim to introduce anti‐ TNF ‐α drugs as well as other novel treatments currently undergoing clinical trials for IBD .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research